This study is looking at how levels of PD-L1 (a protein that can help cancer cells hide from the immune system) in your blood change during immunotherapy for lung cancer. It uses a special blood test called Circulogene liquid biopsy testing to measure PD-L1 and other markers. You may be able to join if you have stage IV or inoperable stage IIIB non-small cell lung cancer (NSCLC) and are starting treatment with an anti-PD-1/L1 immunotherapy, such as a monoclonal antibody. The study aims to see if changes in these blood markers correlate with how well your immunotherapy is working, with results measured for up to 24 months. The study is currently unclear on its recruitment status and plans to enroll 30 participants.

Study design

This is a prospective pilot study, meaning it will follow participants forward in time. It plans to enroll 30 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure results for up to 24 months to see how plasma cfRNA PD-L1 expression correlates with treatment and response.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.